美敦力高管坦言:神经血管业务过去几季承压,主因中国集采及产品召回,两大挑战现已基本化解

美股速递
Feb 17

美敦力管理层在电话会议中透露,公司神经血管业务在过去几个季度面临显著压力,主要受到中国带量采购政策及产品召回事件的双重冲击。不过好消息是,这两大不利因素目前均已基本得到控制,对公司业务的负面影响正逐渐消退。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10